# US 7,611,867 B2 · CC-chemokine binding tick proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,611,867 B2
- Document ID: US7611867B2
- Status: Granted
- Kind: B2
- Application number: 12/096,107
- Filed: 2007-02-16
- Published: 2008-11-20
- Granted: 2009-11-03
- Earliest claimed: 2006-02-16
- Assignees: Merck Serono SA
- Inventors: Amanda Proudfoot; Christine Power; Maud Deruaz
- Web page: https://patentgrep.com/patent/US7611867B2

## CPC

- C07K 14/4703: {Inhibitors; Suppressors}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 33/10: Anthelmintics
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/521: {Chemokines}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A novel CC-chemokine binding protein is isolated from the saliva of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory and immunomodulatory compounds and in the treatment or prevention of CC-chemokine-related diseases.

## Claims

### Claim 1

An isolated polypeptide that:
a) comprises SEQ ID NO: 5;
b) comprises SEQ ID NO: 6; or
c) a fusion protein comprising any one of a) or b) operably linked to a heterologous sequence selected from an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a heterodimeric protein hormone, a signal peptide, an export signal, or a tag sequence.

### Claim 2 (depends on 1)

The isolated polypeptide of claim 1, wherein said polypeptide is post-translationally modified.

### Claim 3 (depends on 2)

The isolated polypeptide of claim 2, wherein said polypeptide is glycosylated.

### Claim 4 (depends on 2)

The isolated polypeptide of claim 2, wherein said polypeptide is PEGylated or coupled to a label or agent.

### Claim 5 (depends on 1)

The isolated polypeptide of claim 1, wherein said polypeptide hinds to a CC-chemokine selected from CCL5 or CCL11.

### Claim 6 (depends on 1)

The isolated polypeptide of claim 1, wherein said polypeptide comprises SEQ ID NO: 5.

### Claim 7 (depends on 1)

The isolated polypeptide of claim 1, wherein said polypeptide consists of SEQ ID NO: 5.

### Claim 8 (depends on 1)

The isolated polypeptide of claim 1, wherein said polypeptide comprises SEQ ID NO: 6.

### Claim 9 (depends on 1)

The isolated polypeptide of claim 1, wherein said polypeptide consists of SEQ ID NO: 6.

### Claim 10 (depends on 1)

The isolated polypeptide of claim 1, wherein said polypeptide is a fusion protein comprising SEQ ID NO: 5 operably linked to a heterologous sequence selected from an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a heterodimeric protein hormone, a signal peptide, an export signal, or a tag sequence.

### Claim 11 (depends on 1)

The isolated polypeptide of claim 1, wherein said polypeptide is a fusion protein comprising SEQ ID NO: 6 operably linked to a heterologous sequence selected from an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a heterodimeric protein hormone, a signal peptide, an export signal, or a tag sequence.

### Claim 12 (depends on 1)

An isolated nucleic acid molecule encoding a polypeptide according to claim 1.

### Claim 13 (depends on 12)

The isolated nucleic acid of claim 12, wherein said nucleic acid encodes a polypeptide comprising SEQ ID NO: 5.

### Claim 14 (depends on 12)

The isolated nucleic acid of claim 12, wherein said nucleic acid encodes a polypeptide consisting of SEQ ID NO: 5.

### Claim 15 (depends on 12)

The isolated nucleic acid of claim 12, wherein said nucleic acid encodes a polypeptide comprising SEQ ID NO: 6.

### Claim 16 (depends on 12)

The isolated nucleic acid of claim 12, wherein said nucleic acid encodes a polypeptide consisting of SEQ ID NO: 6.

### Claim 17 (depends on 12)

The isolated nucleic acid of claim 12, wherein said nucleic acid encodes a fusion protein comprising SEQ ID NO: 5 operably linked to a heterologous sequence selected from an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a heterodimeric protein hormone, a signal peptide, an export signal, or a tag sequence.

### Claim 18 (depends on 12)

The isolated nucleic acid of claim 12, wherein said nucleic acid encodes a fusion protein comprising SEQ ID NO: 6 operably linked to a heterologous sequence selected from an extracellular domain of a membrane-bound protein, an immunoglobulin constant region, a multimerization domain, a heterodimeric protein hormone, a signal peptide, an export signal, or a tag sequence.

### Claim 19 (depends on 12)

The nucleic acid molecule of claim 12, wherein said nucleic acid is a cDNA molecule.

### Claim 20 (depends on 12)

The nucleic acid molecule of claim 12, wherein said nucleic acid comprises SEQ ID NO: 3.

### Claim 21 (depends on 12)

The nucleic acid molecule of claim 12, wherein said nucleic acid comprises SEQ ID NO: 4.

### Claim 22 (depends on 1)

An isolated oligonucleotide that comprises a fragment of at least 30 nucleotides of a nucleic acid molecule encoding a polypeptide of claim 1.

### Claim 23 (depends on 22)

The isolated oligonucleotide of claim 22, wherein said oligonucleotide has a length of at least 50 nucleotides.

### Claim 24 (depends on 1)

A cloning or expression vector comprising a nucleic acid molecule encoding a polypeptide of claim 1.

### Claim 25 (depends on 24)

The expression vector of claim 24, wherein said nucleic acid molecule is operably associated with a promoter.

### Claim 26 (depends on 1)

An isolated transformed host cell comprising a cloning or expression vector comprising a nucleic acid molecule encoding a polypeptide of claim 1.

### Claim 27 (depends on 26)

A process for preparing a polypeptide comprising culturing a host cell of claim 26 under conditions allowing or promoting expression of said polypeptide.

### Claim 28 (depends on 27)

The process of claim 27, further comprising purifying the protein.

### Claim 29 (depends on 27)

The process of claim 27, further comprising formulating the polypeptide into a pharmaceutical composition.

### Claim 30 (depends on 1)

A pharmaceutical composition comprising a polypeptide of claim 1.

### Claim 31 (depends on 1)

A method for immunizing an animal against a blood-feeding ectoparasite, comprising administering to said animal a polypeptide of claim 1 in an amount sufficient to induce an immune response.